News | November 20, 2006

Stem Cell Company Moves Closer to U.S. Cardiac Market

In its third quarter financial report, San Diego-based Cytori said it has moved significantly closer to initiating its cardiovascular clinical trials," said Christopher J. Calhoun, chief executive officer of Cytori Therapeutics. The company is developing adipose stem cells in cardiovascular disease and for use in reconstructive surgery.

"The first trial is expected to start before year end in patients suffering from chronic ischemia, a severe form of coronary artery disease, and the heart attack trial is expected to begin in early 2007.

Cytori received U.S. 510(K) regulatory clearance recently on the Celution Cell Concentration System as a cell saver device by the FDA's Center for Devices and Radiological Health (CDRH)

For more information visit www.cytoritx.com

Related Content

SAVR, surgical aortic valve replacement, elderly patients, aortic stenosis, Society of Thoracic Surgeons, clinical study
News | Structural Heart | January 25, 2017
Elderly patients with aortic stenosis (AS) and medium surgical risk experienced better than expected results after...
Videos | Structural Heart | November 09, 2016
Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance
aortic dissection, family history, same age, clinical study, John A. Elefteriades, Annals of Thoracic Surgery
News | Structural Heart | August 25, 2016
People with a family member who had an aortic dissection — a spontaneous tear in one of the body’s main arteries —...
Videos | Structural Heart | June 30, 2016
Interview with Stephen Little, M.D., medical director of the Valve Clinic at the Houston Methodist DeBakey Heart and
AATS 2016, tricuspid regurgitation, post mitral valve repair, Tirone E. David, atrial fibrillation
News | Structural Heart | May 16, 2016
At the 96th American Association for Thoracic Surgery (AATS) Annual Meeting, investigators presented the results of a...
CABG, mitral valve repair, ischemic mitral regurgitation, IMR, study, ACC 2016
News | Structural Heart | April 11, 2016
Just-released two-year follow-up data comparing coronary-artery bypass grafting (CABG) with combined CABG and mitral-...
V-Wave Interarterial Shunt, first human results, The Lancet, heart failure, HF
News | Structural Heart | March 28, 2016
V-Wave Ltd, maker of an investigational interatrial shunt device for patients with advanced heart failure (HF),...
News | Structural Heart | March 02, 2016
Edwards Lifesciences Corp. announced U.S. Food and Drug Administration (FDA) approval to expand use of the Edwards...
AtriCure, AtriClip, ATLAS study, first patient enrolled, POAF, post-operative atrial fibrillation
News | Structural Heart | February 18, 2016
AtriCure Inc. announced that the first patient was enrolled and treated at PinnacleHealth Hospitals in Harrisburg, Pa...
HeartWare, terminated acquisition, Valtech Cardio
News | Structural Heart | February 10, 2016
February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd.
Overlay Init